Transcription of listed. - CINVANTI™ (aprepitant) injectable emulsion
{{id}} {{{paragraph}}}
Example: barber
listed. - CINVANTI™ (aprepitant) injectable emulsion
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CINVANTITM safely and effectively. See full prescribing information for CINVANTI. CINVANTITM ( aprepitant ) injectable emulsion , for intravenous use Initial Approval: 2003 ----------------------------INDICATIONS AND USAGE---------------------------- CINVANTI is a substance P/neurokinin-1 (NK 1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeatcourses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. (1) nausea and vomiting associated with initial and repeat courses ofmoderately emetogenic cancer chemotherapy (MEC).
5 . 5 WARNINGS AND PRECAUTIONS 5.1 Clinically Significant CYP3A4 Drug Interactions Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: